Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that there is a significant opportunity for a drug that can offer profound improvement in efficacy over Centocor/Schering- Plough/Tanabe's Remicade for the treatment of acute ulcerative colitis. According to the new report entitled Lack of Alternatives to Invasive Surgery Signals Opportunity for Drug Makers: An Acute Ulcerative Colitis Study, an agent that improves on Remicade's efficacy must also offer more convenient administration.
"Physicians demand large improvements in efficacy," said Vickie Lai, analyst at Decision Resources. "A therapy that induces remission in more patients than Remicade must induce remission in at east 40 percent of patients, an improvement of more than 40 percent over Remicade's rate of induction. Physicians do not expect a reduction in side effects, however, as long as the agent offers greater efficacy and more convenient administration. Approximately 75 percent of respondents we surveyed for the report mandate that a new drug be self-administered (either orally or via subcutaneous injections)."
About Lack of Alternatives to Invasive Surgery Signals Opportunity for Drug Makers: An Acute Ulcerative Colitis Study
Lack of Alternatives to Invasive Surgery Signals Opportunity for Drug Makers: An Acute Ulcerative Colitis Study covers the current and future state of the acute ulcerative colitis drug market. The report includes the following:
-- More than 3,000 physician responses that define drug attributes driving prescription now and in the future. -- Clinical end point tradeoffs that are most influential to physicians. -- Areas of unmet need with highest potential. -- Benchmark trial results for specific drug opportunities. -- Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. -- Promotion: DTC spend, detailing intensity. -- Reimbursement: formulary tier, prior approval restriction, quantity limits. -- Labeling: black box warnings, approved patient segments, contraindications. -- Competition: order of entry, pricing, generic entry, pipeline sales forecast. -- Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identify the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/